Atara Biotherapeutics Reports Preclinical Data on ATA3219 to Treat B-Cell Driven Autoimmune Diseases
Shots:
- Atara Biotherapeutics highlights preclinical data of ATA3219 to treat B-cell driven autoimmune diseases at ISCT 2024
- Preclinical results showed cytotoxic activity against CD19 antigen in vitro & in vivo. Compared to an autologous CD19 CAR T benchmark, a strong central memory cell population, CAR-induced B-cell reduction in SLE & MS patient cells with similar potency, and a reduction in inflammatory profile with low secretion of pro-inflammatory cytokines (IFN-γ, TNF-α & IL-6) plus Th2 cytokines (IL-4 & IL-5) was observed
- ATA3219 is being assessed in P-I study for r/r B-cell NHL with initial results anticipated in Q4’24. It will also be investigated in another P-I trial for LN with lymphodepletion & a separate SLE without lymphodepletion arm with initial results anticipated in 2025
Ref: Atara Biotherapeutics | Image: Atara Biotherapeutics
Related Posts:- Atara Biotherapeutics Reports Results for ATA188 in P-II Trial for the Treatment of Non-Active Progressive Multiple Sclerosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
